The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
**Background:** There are sparse data addressing whether standard risk factors for febrile neutropenia (FN) are relevant in patients receiving myelosuppressive chemotherapy and primary prophylaxis for FN, which would have implications for variables to consider during real-world comparative analyses...
Auteurs principaux: | Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang |
---|---|
Format: | Article |
Langue: | English |
Publié: |
Columbia Data Analytics, LLC
2021-06-01
|
Collection: | Journal of Health Economics and Outcomes Research |
Accès en ligne: | https://jheor.scholasticahq.com/article/24564-the-impact-of-baseline-risk-factors-on-the-incidence-of-febrile-neutropenia-in-breast-cancer-patients-receiving-chemotherapy-with-pegfilgrastim-prophy.pdf |
Documents similaires
-
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
par: Edward Li, et autres
Publié: (2021-06-01) -
Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis
par: Giovanni Rosti, et autres
Publié: (2011-09-01) -
On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status
par: Ivo Abraham, et autres
Publié: (2024-01-01) -
Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
par: Patrizia Berto, et autres
Publié: (2022-02-01) -
Incidence and Impact of Baseline Electrolyte Abnormalities in Patients Admitted with Chemotherapy Induced Febrile Neutropenia
par: Asim Jamal Shaikh, Samira Ahmed Bawany, Nehal Masood, Ausaf Ahmed Khan, Ahmed Nadeem Abbasi, Syed Najeeb Niamutullah, Adnan Zaidi, Salman Adil, Shiyam Kumar
Publié: (2011-01-01)